Ntrk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-gene
Symbol: NTRK2
Full Name: Neurotrophic Receptor Tyrosine Kinase 2
Chromosomal Location: 9q21.33
NCBI Gene ID: 4915
OMIM: 191322
Ensembl ID: ENSG00000157184
UniProt: Q16620
Proteins: TrkB
Associated Diseases: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Depression
::
NTKR2 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of NTKR2 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
NTRK2 encodes TrkB (Tropomyosin receptor kinase B), the primary receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). TrkB is a receptor tyrosine kinase critical for synaptic plasticity, memory formation, and neuronal survival. BDNF/TrkB signaling is implicated in multiple neurodegenerative diseases, and enhancing this pathway is a therapeutic strategy being explored for AD, PD, and HD.
TrkB is expressed in:
- Hippocampus (CA1-CA3, dentate gyrus)
- Cerebral cortex (layers II-III, V-VI)
- Basal forebrain cholinergic neurons
- Striatum
- Substantia nigra pars compacta
- Cerebellum (Purkinje cells)
Wide expression in limbic system and reward pathways explains its role in learning, memory, and mood.
- Klein R, et al. (1989). "The trkB tyrosine protein kinase encodes a receptor for brain-derived neurotrophic factor." Neuron. PMID:2535250
- Huang EJ, et al. (2001). "TrkB signaling in cortical development." Ann Neurol. PMID:11726961
- Zuccato C, et al. (2011). "Neurotrophins in Huntington's disease: role in the pathogenesis and as potential therapeutic targets." Mech Ageing Dev. PMID:21195753
The study of Ntrk2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ly C et al.. "Psychedelics Promote Structural and Functional Neural Plasticity." Cell reports (2018). DOI: 10.1016/j.celrep.2018.05.022 PubMed: 29898390
- Taylor KR et al.. "Glioma synapses recruit mechanisms of adaptive plasticity." Nature (2023). DOI: 10.1038/s41586-023-06678-1 PubMed: 37914930
- Fatt MP et al.. "Morphine-responsive neurons that regulate mechanical antinociception." Science (New York, N.Y.) (2024). DOI: 10.1126/science.ado6593 PubMed: 39208104
- Moliner R et al.. "Psychedelics promote plasticity by directly binding to BDNF receptor TrkB." Nature neuroscience (2023). DOI: 10.1038/s41593-023-01316-5 PubMed: 37280397
- Ma ZZ et al.. "Enhanced ERK activity extends ketamine's antidepressant effects by augmenting synaptic plasticity." Science (New York, N.Y.) (2025). DOI: 10.1126/science.abb6748 PubMed: 40339008
- Geoffroy H, Noble F. "BDNF During Withdrawal." Vitamins and hormones (2017). DOI: 10.1016/bs.vh.2016.10.009 PubMed: 28215305
- Ye W et al.. "Association of NTRK2 gene with suicidality: a meta-analysis." Psychiatric genetics (2024). DOI: 10.1097/YPG.0000000000000373 PubMed: 39527116
- Clark VD et al.. "Hyperfibrinogenemia-mediated astrocyte activation." Brain research (2018). DOI: 10.1016/j.brainres.2018.08.023 PubMed: 30153459